Roth Capital Bumps PT on Ligand Pharma (LGND) up to $151 Following Sparsentan Data; Affirms at 'Buy'
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Roth Capital boosts its price target on Buy-rated Ligand Pharmaceuticals (Nasdaq: LGND) from $149 to $151 after the company announced positive data from the sparsentan Phase II study in FSGS patients.
Analyst Joseph Pantginis commented today,
This is an important win for RTRX/LGND and management indicated that efficacy for sparsentan exceeded expectations (projected 50% improvement, where a >two-fold improvement was seen) and irbesartan performed as expected. RTRX is now looking to engage regulatory authorities to define the most accelerated path forward for the drug. Based on the unmet medical need (no approved therapies for FSGS), we still project accelerated approval in 2017 for the launch and look forward to regulatory visibility. Where we believe our projections are conservative revolves around or peak sales estimate. We currently project $425 million in peak sales. For the U.S. market this represents ~12% market penetration based on $100,000 per year treatment cost. If sparsentan represents the first potential drug approved for FSGS, we believe the penetration rate could be much higher. Looking forward we continue to highlight the readout of the Kyprolis Phase III CLARION study later this year as well as the internal initiation of the Phase II for LGD-6972 for diabetes this quarter.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Cuts Price Target on Workday (WDAY) Following 3Q; Reiterates Outperform
- Pivotal Research Downgrades Kroger (KR) to Hold
- BTIG Cuts PT on Workday (WDAY) to $88 Following Q3 Results; Affirms at 'Buy'
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!